Freedom Capital Markets initiated coverage on Hinge Health Inc (NYSE:HNGE), assigning a Buy rating and setting a price target at $59.00, which suggests an approximate 41% increase relative to the present share price of $41.77. Analyst price targets noted within InvestingPro data range broadly from $48 to $72, reflecting varied but positive projections.
The firm characterized Hinge Health as a prominent player in the digital-first musculoskeletal (MSK) therapy field, with the company purportedly growing at an estimated 23% annual pace this year. With a market capitalization standing at $3.27 billion, Hinge Health demonstrates a strong gross profit margin of 78.82%, figures that align with Freedom Capital’s margin predictions.
According to Freedom Capital Markets, Hinge Health is only beginning to tap into a market valued at more than $60 billion, indicating ample room for continued growth and enhanced market penetration. The firm anticipates the company will continue to outperform throughout 2026, buoyed by a balance sheet showing cash exceeding debt, which could facilitate further expansion in its sector.
As Hinge Health scales, the research firm projects the company’s margins will expand, forecasting leading software-like gross margins between 82% and 83%. This margin improvement is largely attributed to the business model's scalability and operational efficiencies.
Investors are advised by Freedom Capital Markets to consider purchasing shares amid the current price softness, with confidence in the company's expected 23% growth trajectory this year.
Additional analyst support complements this outlook. Canaccord Genuity has reaffirmed a Buy rating on Hinge Health and set a price target of $65.00 ahead of the company’s upcoming fourth-quarter earnings. This endorsement follows positive dialogue with corporate executives, suggesting confidence in long-term prospects.
Similarly, Stifel has maintained its Buy rating, drawing attention to insights from Hinge Health’s annual report on musculoskeletal care, which identifies significant shortcomings in traditional healthcare approaches. Piper Sandler, while lowering its price target to $60.00 from $71.00, continues to rate the stock as Overweight, reflecting tweaks in financial guidance and customer behavior metrics.
Wells Fargo recently initiated coverage with an Overweight recommendation and established a $68.00 price target, highlighting Hinge Health’s leadership role within the musculoskeletal category. Meanwhile, Needham named Hinge Health its leading health technology pick for 2026, echoing a Buy rating with a $59.00 price target. Collectively, these analyst evaluations reinforce a strong positive sentiment toward Hinge Health’s market positioning and growth potential.